Table 1.

EGFR inhibitors

Inhibitor	Manufacturer	Class	Specificity	FDA indication and year of approval
Cetuximab C225, Erbitux®	ImClone Systems	Mouse-human chimeric antibody	EGFR	EGFR-expressing mCRC in patients refractory to irinotecan-based chemotherapy (2004) Locally or regionally advanced HNSCC in combination with radiotherapy (2006)
Matuzumab EMD72000	EMD Pharmaceuticals	Mouse-human chimeric antibody	EGFR	Not yet approved
Nimotuzumab h-R3, TheraCIM®	YM BioSciences	Human antibody	EGFR	Not yet approved
Panitumumab ABX-EGF, Vectibix®	Amgen	Human antibody	EGFR	EGFR-expressing mCRC with progression on or following chemotherapy regimens containing fluoropyrimidine, oxaliplatin, and irinotecan (2006)
Zalutumumab HuMax-EGFr	Genmab	Human antibody	EGFR	Not yet approved
Erlotinib OSI-774, Tarceva®	Genentech	Anilinoquinazoline- based reversible inhibitor	EGFR	NSCLC as a monotherapy after failure of at least one prior chemotherapy (2004) Advanced pancreatic cancer in combination with gemcitabine for patients who have not received previous chemotherapy (2005)
Gefitinib ZD1839, Iressa®	AstraZeneca	Anilinoquinazoline- based reversible inhibitor	EGFR	Locally advanced metastatic NSCLC cancer after failure of both platinum- based and docetaxel chemotherapies (2003)
Vandetanib ZD6474, Zactima®	AstraZeneca	Anilinoquinazoline- based inhibitor	EGFR VEGFR2 RET- tyrosine kinase	NSCLC Submitted for approval in June 2009, but application withdrawn in October 2009 in NSCLC setting with chemotherapy
Lapatinib GW572016, Tykerb®	GlaxoSmithKline	Thiazolylquinazoline- based reversible inhibitor	EGFR HER2	Metastatic breast cancer in combination with capecitabine whose tumors overexpress HER2 and have received prior therapy, including an anthracycline, a taxane, and trastuzumab (2006)
Pelitinib EKB-569	Wyeth	Cyanoquinoline-based irreversible inhibitor	EGFR HER2	Not yet approved

Abbreviations: HNSCC, head and neck squamous cell carcinoma; mCRC, metastatic colorectal cancer; NSCLC, non-small cell lung cancer;